Decreased Choroidal Thickness in Vitiligo Patients: Researcharticle Open Access
Decreased Choroidal Thickness in Vitiligo Patients: Researcharticle Open Access
Decreased Choroidal Thickness in Vitiligo Patients: Researcharticle Open Access
Abstract
Background: Vitiligo is a disease characterized by depigmented macules and patches that occur as a result of the loss
of functional melanocytes from the affected skin through a mechanism which has not been elucidated yet. Destruction
of pigment cells in vitiligo may not remain limited to the skin; the eyelashes, iris, ciliary body, choroid, retinal pigment
epithelium and meninges may also be affected. This study aims to compare the choroidal thickness of patients with
and without vitiligo using optical coherence tomography (OCT).
Methods: Spectral-domain optical coherence tomography (SD-OCT) (Retina Scan Advanced RS-3000 NIDEK, Japan)
instrument (with λ = 840 nm, 27,000 A-scans/second and 5 μm axial resolution) was used for the imaging. Statistical
analysis was performed using SPSS 21.0 software package.
Results: In all values except optic nevre area measurements, the choroidal thickness of all vitiligo patients was found
out to be thinner compared to the control group.
Conclusions: In vitiligo, the choroidal thickness may be affected by the loss of melanocytes.
Keywords: Vitiligo, Choroidal thickness, OCT, VASI, Oculocutaneous disease
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Demirkan et al. BMC Ophthalmology (2018) 18:126 Page 2 of 6
Destruction of pigment cells in vitiligo may not remain diabetes, cigarette use, hypertension, antihypertensive
limited to the skin; the eyelashes, iris, ciliary body, chor- drug use, known atherosclerotic disease, pregnancy,
oid, retinal pigment epithelium and meninges may also macular degenerations, previous ocular surgery, choroidal
be affected [10]. Low choroidal thickness may be ex- pathology, glaucoma, high refractive error (patients with
pected in vitiligo where melanocyte loss proceeds [10]. more than + 6 and −6 diopters as cycloplegic spherical
Although there have been many studies conducted to equivalent), best corrected visual acuity below 20/25, and
evaluate choroidal thickening in diseases that affected patients with a systemic other disease were not in-
eye vasculature, limited research has been conducted on cluded in this study. Spectral-domain optical coher-
the diseases that affect melanocytes and another compo- ence tomography (SD-OCT) (Retina Scan Advanced
nent of choroidal tissue, which remained under-researched. RS-3000 NIDEK, Japan) instrument (with λ = 840 nm,
This study aims to compare the choroidal thickness of 27,000 A-scans/second and 5 μm axial resolution)
patients with and without vitiligo using optical coher- was used for the imaging.
ence tomography (OCT). Before evaluation, using EDI-OCT scanning, the cen-
tral macular thickness was measured in the right eye of
Methods each patient. Choroidal and scleral boundaries were
This prospective clinical study addresses the examin- drawn with the assistance of software programs. Chor-
ation of the bilateral eyes of (154 eyes). A total of 77 in- oidal thickness was measured at the center of the fovea
dividuals, including 34 vitiligo and 43 non-vitiligo, were (SubF), and 500 μm nasally, temporally, superiorly and
included in the study. This study was carried out be- inferiorly (N1, T1, S1, I1), and 1500 μm (N2, T2, S2, I2)
tween 2015 and 2016 in accordance with the tenets of from the center of the fovea. The peripapillary region
the Declaration of Helsinki. The study protocol was ap- was measured 500 μm (N, T, S, I) from the center of
proved by the Local Ethical Committee of the University the optic nerve. The averages of upper hemifield, lower
of Kırıkkale. All patients and control subjects voluntarily hemifield, and whole hemifield of the peripapillary re-
participated in this study and signed an informed con- gion were also measured (Fig. 1a, b). The foveal and
sent form. parafoveal choroidal thickness was determined by
Patients, who were diagnosed with vitiligo and were measuring the region between the outer border of the
aged between 20 and 50 years, and non-vitiligo adults retinal pigment epithelium layer and the sclero-choroidal
with similar characteristics participated in this study. interface manually. Measurements in the peripapillary
VASI (vitiligo area severity index), which shows the de- area were carried out automatically with the instrument.
pigmentation extent, was calculated in all vitiligo pa- The values of the right and left eyes of the patient and
tients [11]. The percentage of the body area involved can control group were separately specified and compared. All
be estimated by the so-called 1% rule or “palm method”. measurements are presented with median, minimum and
In both children and adults, the palm of the hand, in- maximum values.
cluding the fingers, is approximately 1% of the total body Statistical analysis was performed using SPSS 21.0 soft-
surface area (TBSA), and it describes hand unit [11]. For ware package. Descriptive statistics were presented as a
each body region, the VASI was determined by the prod- mean ± standard deviation. In comparisons between pa-
uct of the area of vitiligo in hand units and the extent of tient and control groups, the student’s t-test was applied
depigmentation within each hand unit–measured patch to numerical data that followed a normal distribution,
(possible values of 0, 10, 25, 50, 75, 90% or 100%). The while the Mann-Whitney U test was applied to data
total body VASI was calculated using the following for- that did not follow a normal distribution. The Pearson
mula considering the contributions of all body regions correlation test was applied to normally distributed
(possible range, 0–100): measurements, and the Spearman correlation test was
X applied to data that did not follow a normal distribu-
VASI ¼ All Body Sites ½Hand Units tion. The statistical significance value was accepted as
½Residual Depigmentation p < 0.05.
Table 1 Age and sex distrubation, intraocular pressure, axial length, visual acuity, refraction defect values of the patients and
control group
Patients (n:34) Control group (n:43) P value
(mean±) (mean±)
Age 39.2 ± 16.14 39.3 ± 12.51 0.101*
Sex(F/M) 15:19 (44%:56%) 20:23 (46%:54%)
Right intraocular pressures 14.20 ± 3.31 15.00 ± 2.23 0.105*
Left intraocular pressures 14.55 ± 2.83 14.76 ± 2.09 0.347*
Axial length 23.57 ± 1.04 23.58 ± 1.22 0.960*
Right eyes visual acuity 0.07 ± 0.21 −0.01 ± 0.26 0.330*
Left eyes visual acuity 0.08 ± 0.22 0.06 ± 0.40 0.845*
Right eye refraction defect − 0.37 ± 1.00 0.00 ± 0.92 0.184*
Left eyes refraction defect −0.21 ± 0.97 − 0.01 ± 0.98 0.702*
*…Student’s t test
Demirkan et al. BMC Ophthalmology (2018) 18:126 Page 4 of 6
Table 2 Mean choroidal thickness in vitiligo patients and control group individuals
Patient (n:34) Control (n:43) P value
Mean ± SD Minimum Median Maximum Mean ± SD Minimum Median Maximum
Right, SubF 220.2 ± 39.8 170 224 290 261.4 ± 31.1 168 256 305 < 0.001**
Right, N1 223.6 ± 42.1 163 220 276 258.4 ± 32.5 190 248 302 < 0.001**
Right, N2 226.0 ± 39.2 130 220 340 261.5 ± 37.4 200 265 361 < 0.001*
Right, T1 220.5 ± 39.9 143 224 303 257.9 ± 34.2 139 257.5 311 < 0.001**
Right, T2 225.2 ± 41.1 109 220 280 253.4 ± 32.3 200 250 327 0.001*
Right, S1 222.9 ± 44.6 142 219 296 268.7 ± 38.1 198 271 289 < 0.001**
Right, S2 217.8 ± 40.8 151 219 301 259.1 ± 33.4 201 261 306 < 0.001**
Right, I1 223.4 ± 45.2 119 221 289 266.3 ± 37.0 136 264 321 < 0.001**
Right, I2 224.5 ± 45.2 117 226 340 265.9 ± 34.9 200 260 360 < 0.001*
Right optic nerve, LowH 95.0 ± 15.4 34 96 138 97.5 ± 7.9 80 97 118 0.429*
Right optic nerve, UpH 80.2 ± 16.8 43 81 128 77.1 ± 16.8 41 79 135 0.418**
Right optic nerve, WholP 98.9 ± 15.2 47 97 134 100.5 ± 8.1 54 101 126 0.805*
Right optic nerve, N 80.2 ± 16.8 54 77.5 126 77.1 ± 16.8 33 75 117 0.418**
Right optic nerve, T 68.9 ± 14.1 45 68 104 68.4 ± 15.5 29 69 99 0.689*
Right optic nerve, S 128.9 ± 25.3 59 132 168 129.4 ± 16.5 95 129 175 0.712*
Right optic nerve, I 118.9 ± 23.6 21 125.5 175 125.6 ± 17.0 79 125 165 0.230*
Left, SubF 222.7 ± 37.3 118 223 296 269.1 ± 31.0 129 267 305 < 0.001**
Left, N1 223.7 ± 38.5 105 224 301 271.7 ± 36.1 119 269 301 < 0.001**
Left, N2 228.2 ± 39.6 106 227 298 265.4 ± 35.8 129 267 311 < 0.001**
Left, T1 227.2 ± 42.2 164 226.5 380 308.2 ± 30.8 210 265 291 < 0.001*
Left, T2 235.4 ± 38.3 131 234 324 272.7 ± 35.7 176 275 329 < 0.001**
Left, S1 215.3 ± 40.2 126 216 305 257.2 ± 35.2 161 254 298 < 0.001**
Left, S2 220.0 ± 37.6 137 219 299 249.5 ± 48.2 148 251 324 0.005**
Left, I1 216.5 ± 38.0 139 218 301 262.3 ± 31.7 167 264 341 < 0.001**
Left, I2 222.2 ± 37.1 170 220 344 262.8 ± 31.9 210 260 350 < 0.001*
Left optic nerve, LowH 94.8 ± 12.2 59 95 141 95.5 ± 11.0 48 97 173 0.955*
Left optic nerve, UpH 122.6 ± 19.5 75 96 124 127.3 ± 16.3 77 93 125 0.255**
Left optic nerve, WholP 98.1 ± 12.0 70 99 125 100.2 ± 11.7 79 101 133 0.655*
Left optic nerve, N 75.6 ± 21.6 30 78 126 82.1 ± 23.7 27 78 174 0.432*
Left optic nerve, T 66.0 ± 18.1 35 61.5 106 65.0 ± 14.3 38 66 95 0.782*
Left optic nerve, S 128.4 ± 19.9 81 131.5 162 128.6 ± 20.5 76 131 178 0.951*
Left optic nerve, I 122.6 ± 19.5 89 122 169 127.3 ± 16.3 97 127 174 0.310*
*…Mann Whitney U test
**…Student’s t test
relevant literature on this subject, we have not seen Ethics approval and consent to participate
any published studies that would allow us to make a This study was carried out between 2015 and 2016 in accordance with the
direct comparison regarding our findings. The lack of tenets of the Declaration of Helsinki. The study protocol was approved by
the Local Ethical Committee of the University of Kırıkkale. All patients and
differences between the vitiligo patients and the con- control subjects voluntarily participated in this study and signed an informed
trol group in optic nerve regions may be because me- consent form.
lanocytes occupy less space in the histological
Competing interests
structure in the optic nerve regions. The authors declare that they have no competing interests.
Some studies maintained that gender and hormonal
status may influence choroidal blood flow and lead to
Publisher’s Note
change in the choroidal thickness [26, 27]. However, in Springer Nature remains neutral with regard to jurisdictional claims in
our study, it was observed that gender resulted the dif- published maps and institutional affiliations.
ference in choroidal thickness neither in the vitiligo pa-
Author details
tients group nor the control group. 1
Department of Dermatology and Venerology, Kirikkale University Faculty of
Many authors have reported that the reasons for the Medicine, Yenisehir District, Tahsin Duru Avenue, No:14, Yahsihan, Kirikkale,
Turkey. 2Department of Ophtalmology, Kirikkale University Faculty of
differences in the choroidal thickness results between
Medicine, Yenisehir District, Tahsin Duru Avenue, No:14, Yahsihan, Kirikkale,
studies are different software programs for measure- Turkey.
ment, differences in the light source of the OCT, ethnic
Received: 14 December 2017 Accepted: 23 May 2018
differences, differences in the age, refraction defects and
axial length in the patient profile [14–20]. However,
since a comparison was made with the control group, References
and the characteristics of the patient and control group 1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive
overview part I. Introduction, epidemiology, quality of life, diagnosis,
were similar, the findings suggest that comparison of the diferantial diagnosis, associations, histopathology, etiology, andwork-up. J
measurements resulted in useful data. Am Acad Dermatol. 2011;65(3):473–91.
Demirkan et al. BMC Ophthalmology (2018) 18:126 Page 6 of 6